Clinical Trial Update: The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study [Phase 3]

View source ↗

Summary

Phase 3 safety update for the GSK-580299 vaccine focusing on the control group in the primary NCT01249365 study; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections
• Papillomavirus

Drugs mentioned

• GSK-580299

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2018-07-16